FDA fast-tracks drug for autism cause Fragile X syndrome
The US Food and Drug Administration (FDA) has granted Fast Track designation to SPG601 for the treatment of people with Fragile X syndrome (FXS).
FXS, a known cause of autism, is the leading inherited form of intellectual disability that can produce a wide range of disabling symptoms, with many individuals requiring lifelong around-the-clock supportive care.
SPG601 works at the synaptic level, targeting a well-established molecular dysfunction in FXS.
It is a small molecule large-conductance, calcium-activated potassium (BK) channel activator that works by binding to BK channels and increasing their activation to correct specific synaptic dysfunctions that underlie many core symptoms of FXS.
“I am thrilled that the FDA has granted Fast Track designation to SPG601 for FXS, highlighting its potential as a novel therapeutic option for a disease that, to this day, has no approved treatment,” said Dr Craig Erickson, Spinogenix Chief Medical Advisor and principal investigator of the recently completed Phase II study conducted at Cincinnati Children’s. “The possibility that SPG601 could address underlying synaptic deficits central to this condition in people with FXS brings immense hope, and with this designation, we are even closer to making it available to patients sooner.”
In 2024, the FDA granted Orphan Drug designation to SPG601 for the treatment of FXS. With this Fast Track designation, Spinogenix can expedite the development and review of SPG601 in FXS.
Phase II study of SPG601
Spinogenix recently completed a Phase II study of SPG601 in adult men with FXS, with topline results expected by end of Q1 2025.
The study was designed to enable the detection of meaningful brain target engagement in first-in-human FXS trials, utilising validated neurophysiologic markers of brain activity. These markers have been extensively validated over the past decade by Dr Erickson and colleagues, supported by the National Institutes of Health Centers for Collaborative Research in Fragile X program.
“Receiving Fast Track designation for SPG601 demonstrates its potential to impact patients’ lives and brings us one step closer to providing a new therapeutic to combat FXS,” said Dr Stella Sarraf, Spinogenix Chief Executive Officer and Founder. “We also believe our core technology can play a similar future restorative role across additional disease states.”
Diana Spencer, Senior Digital Content Editor, DDW
